The Pharmaceutical and Medical Devices Agency (PMDA), Japan has completed the Good Manufacturing Practices (GMP) inspection at Lupin’s Mandideep facility (Unit-2). The inspection was conducted between May 14, 2019 and May 17, 2019. The PMDA inspection closed with no critical or major observations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.